Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.100
+0.279 (33.90%)
At close: Nov 20, 2024, 4:00 PM
0.971
-0.129 (-11.75%)
Pre-market: Nov 21, 2024, 5:49 AM EST
Coherus BioSciences Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Coherus BioSciences stock have an average target of 6.13, with a low estimate of 1.50 and a high estimate of 12. The average target predicts an increase of 457.27% from the current stock price of 1.10.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CHRS stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 1 | 1 | 2 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $8 → $4 | Buy | Maintains | $8 → $4 | +263.64% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +990.91% | Nov 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +990.91% | Sep 16, 2024 |
| UBS | UBS | Strong Buy → Hold Downgrades $4 → $1.5 | Strong Buy → Hold | Downgrades | $4 → $1.5 | +36.36% | Aug 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $12 | Strong Buy | Reiterates | $12 | +990.91% | Aug 5, 2024 |
Financial Forecast
Revenue This Year
265.81M
from 257.24M
Increased by 3.33%
Revenue Next Year
310.39M
from 265.81M
Increased by 16.77%
EPS This Year
-0.91
from -2.53
EPS Next Year
-0.22
from -0.91
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 314.0M | 437.9M | 454.7M | ||
| Avg | 265.8M | 310.4M | 354.8M | ||
| Low | 238.3M | 235.5M | 229.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 22.0% | 64.7% | 46.5% | ||
| Avg | 3.3% | 16.8% | 14.3% | ||
| Low | -7.4% | -11.4% | -26.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.32 | 0.22 | 0.39 | ||
| Avg | -0.91 | -0.22 | 0.08 | ||
| Low | -2.17 | -0.77 | -0.10 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.